Baxter International Inc. (BAX)

[mlkrborn]

Baxter Approves ADVATE as the only FVIII for routine Prophylaxis in both Adults and Children With Hemophilia A (BAX) 48.36 : Co announced that the FDA has approved ADVATE for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A. ADVATE is the only antihemophilic factor approved in the United States for prophylactic use in both adults and children. The study findings demonstrated a statistically significant reduction in the median annual bleeding rate, with patients experiencing 44 bleeds during on-demand treatment compared to one bleed while on either of the prophylactic regimens evaluated, a 98 percent reduction in annual bleed rate.